Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart
  • Log out

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The impact of obstructive sleep apnoea on the aorta

Thomas Gaisl, Daniel J. Bratton, Malcolm Kohler
European Respiratory Journal 2015 46: 532-544; DOI: 10.1183/09031936.00029315
Thomas Gaisl
1Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Bratton
1Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malcolm Kohler
1Dept of Pulmonology, University Hospital Zurich, Zurich, Switzerland
2Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
3Centre for Interdisciplinary Sleep Research, University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Malcolm.Kohler@usz.ch
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Obstructive sleep apnoea (OSA) has been shown to be a causal factor in the pathogenesis of vascular dysfunction and hypertension, conditions which can promote dilation and subsequent aortic dissection and rupture. The objective of this review is to summarise the current literature on the possible association between OSA and aortic disease and delineate the underlying mechanisms.

Relevant studies were found by searching for terms including “obstructive sleep apnoea” in combination with “aortic aneurysm, dissection, and dilation” in the MEDLINE and EMBASE databases.

Observational studies consistently reported that OSA is highly prevalent among patients with aortic aneurysms and aortic dissections. Patients with co-occurring OSA and Marfan's syndrome as well as patients at the more severe end of the spectrum of OSA seem to be especially vulnerable to aortic disease.

Several mechanisms are discussed concerning the link between OSA and aortic disease: nocturnal negative intrathoracic pressure surges leading to mechanical stretching of the aorta and ultimately aortic distension; arousal-induced reflex sympathetic activation with subsequent hypertension; and intermittent hypoxia associated with autonomic nervous system activation and consequently increased oxidative stress. Further well controlled studies are needed in order to define the exact role of OSA as a risk factor for aortic disease.

Abstract

Several studies have shown an association between obstructive sleep apnoea and aortic aneurysms/dissections http://ow.ly/Nh9jc

Introduction

Obstructive sleep apnoea (OSA) is highly prevalent, with at least 20% of males and 10% of females in Western countries affected by asymptomatic OSA [1–4]. Pathophysiologically, the disease is characterised by repetitive partial or complete obstruction of the pharynx during sleep. Despite increasing breathing efforts the upper airway collapse results in episodes of obstructive hypopnoeas or apnoeas affecting the sleep architecture and the whole body via instant and long-term mechanisms.

Determining the potential contribution of OSA to cardiovascular risk is challenging. A large proportion of research on OSA is dedicated to cardiovascular consequences, where a causal relationship between OSA, major adverse cardiovascular events [5–7], heart failure [5] and mortality [8] has been suggested yet not definitely established. By contrast, OSA has been confirmed to be a causal factor in the pathogenesis of vascular dysfunction and hypertension [9, 10]. Cohort studies including the Sleep Heart Health Study have consistently demonstrated that over 50% of individuals with OSA have hypertension [1, 11, 12]. Sustained and effective treatment of OSA with continuous positive airway pressure (CPAP) has been reported to improve daytime symptoms and quality of life [13, 14] and to reduce blood pressure [15], one of the major risk factors for aortic dilation [16].

An aortic aneurysm is defined as a permanent, localised dilation of the aorta that includes all three layers of the vessel [17]. The prevalence of thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA) is 0.16–0.34% [18, 19] and 1.2% [20], respectively, with a markedly higher prevalence in men aged >60 years. Currently, aortic aneurysms in general represent the 18th leading cause of death in the USA [21]. Pathogenesis and treatment differ slightly for aortic aneurysms depending on the exact location [22]; however, about 25% of patients with TAA also have AAA, suggesting similar risk factors for both diseases [23]. Aortic aneurysms represent a group of disorders resulting from connective tissue diseases, inflammatory components [24], hypertension and atherosclerosis [23, 25] and are associated with high rates of morbidity and mortality due to dissection and/or rupture [23, 26]. Besides the treatment of the underlying risk factors, elective repair of large-diameter aneurysms and aneurysms with a high expansion rate is recommended. Because aneurysms are usually asymptomatic, a timely detection and knowledge of the underlying risk factors is crucial.

The potential impact of OSA on cardiovascular burden and aortic disease is likely to be related in large part to its association with elevated blood pressure. Ambulatory blood pressure is particularly elevated during sleep compared with the awake period and OSA patients often present a non-dipping pattern (diminished nocturnal blood pressure fall) or riser pattern (sleep blood pressure higher than awake blood pressure) of nocturnal blood pressure [27]. Regardless of how blood pressure is measured, there is a significant association between OSA severity and elevated blood pressure [28]. It is generally accepted that hypertension can cause thoracic aortic dilation [29] and is the main risk factor for aortic dissection (AD) [26], although the exact pathophysiology remains unclear. Chronic hypertension and its vascular consequences are major yet fractional risk factors, since it is not rare for aortic disease to also develop in adequately treated patients [22, 30]. It is therefore thought that OSA may act through a number of other pathomechanisms to elicit vascular damage. However, because of the association between common risk factors (e.g. age, male sex, hypertension, etc.) and both OSA [1, 31–33] and aortic disease [23, 25, 30], it is difficult to establish the true effect of OSA.

The purpose of this review is to summarise the clinical evidence and synthesise the pathophysiological mechanisms between OSA and aortic disease, namely: 1) aortic dilation, 2) aortic aneurysms (TAA and AAA), and 3) AD. The aim is to provide clinicians with a clear picture of the current literature on this topic, discuss potential implications for clinical practice and highlight areas of future research for this highly prevalent sleep disorder.

Methods

Inclusion criteria

Studies were eligible if they covered (at least in one aspect) the topic of the impact of OSA on aortic disease (aortic dilation, AD, TAA, AAA) or vice versa. Studies in humans and in English published until January 1, 2015 were considered for this review. We did not include case reports, reviews, conference abstracts and studies investigating aortic stiffness. No other restrictions were used.

Search strategy

We performed electronic database searches in MEDLINE (Ovid version, New York, NY, USA) and EMBASE (DataStar Version, Cary, NC, USA). The search was conducted using the following medical subject heading (MeSH) terms: “obstructive sleep apnea” in combination with “aortic dila(ta)tion”, “aortic aneurysm” and “aortic dissection”, including alternative MeSH entry terms. The bibliographies of all articles that fulfilled the inclusion criteria were screened to identify other articles that fulfilled the inclusion criteria.

Results

Searches of electronic databases identified 23 eligible studies with a total of 2800 patients. Figure 1 shows the flow diagram for identification of relevant studies. Complete search results are available in the online supplementary material (table S1). In this results section, the evidence from clinical studies on the impact of OSA on aortic disease will be reviewed, followed by a discussion of the potential underlying mechanisms.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Flow diagram for identification of relevant studies.

Evidence from clinical studies on the impact of OSA on aortic disease

Marfan's syndrome

Research on the impact of OSA on aortic disease is based upon early studies in patients with Marfan's syndrome. Marfan's syndrome is a genetic multisystem connective tissue disorder associated with craniofacial abnormalities and increased upper airway collapsibility, both of which are linked to OSA [34–37]. Aortic dilation and associated AD and rupture are the main cause of morbidity and mortality in patients with Marfan's syndrome, cutting life expectancy by about one third compared with the general population [38, 39]. In 1993, it was first suspected by Cistulli and Sullivan [40] that OSA might have deleterious effects on aortic dilation and subsequent rupture. They attributed, at least in part, the reduced life expectancy due to aortic complications to the high OSA prevalence among patients with Marfan's syndrome [40]. Later, a considerably high OSA prevalence in patients with Marfan's syndrome was confirmed and a moderate correlation between the apnoea–hypopnoea index (AHI) and maximal aortic root diameter was found (r=0.5, p<0.001, 95% CI 0.2–0.69) [41, 42]. A follow-up study in 44 patients with Marfan's syndrome was then performed to further explore the longitudinal association between OSA and aortic disease [43]. After a median follow-up time of 29 months, only subjects with OSA developed an aortic event, defined as an operation because of progressive aortic dilation or death because of aortic rupture. The AHI was associated with aortic events in univariable analysis (hazard ratio 1.09, 95% CI 1.01–1.18), but not when other covariates (age, sex, systolic blood pressure, antihypertensive medication, baseline aortic diameter) were accounted for, possibly due to a lack of statistical power [43]. Up to now, this represents the only longitudinal study where the impact of OSA on aortic disease (by means of events rather than disease parameters) has been investigated.

General population

Studies in the general population show a somewhat mixed body of evidence (table 1). Most of the studies investigated the association between OSA and the aortic root diameter [44–52]. Six cross-sectional studies investigating patients referred for a sleep evaluation reported a positive association between the aortic root diameter and parameters of OSA severity (either AHI or oxygen desaturation index (ODI)) [45, 48–52]. Notably, one study found an association with AHI in rapid eye movement sleep only where the severity of OSA becomes greater, partly due to a decreased respiratory muscle tone [52]. Another study reported this association in patients with hypertrophic cardiomyopathy [48].

View this table:
  • View inline
  • View popup
TABLE 1

Current evidence from clinical studies on the impact of obstructive sleep apnoea (OSA) on aortic disease

By contrast, two prospective [44, 47] and one retrospective study [46] did not establish the aforementioned relationship. Tanriverdi et al. [44] reported no difference in aortic diameters (systolic/diastolic) in a matched OSA case–control study. This finding is in agreement with another retrospective study that assessed aortic diameter in 76 OSA patients and found age and sex to be the only determinants for aortic root dilation [46]. However, 84% of these patients were treated with CPAP, which is likely to dilute the association between AHI and aortic diameter [46]. Another study investigated patients with acute myocardial infarction for an association between OSA and aortic diameter [47]. Stepwise multivariable regression revealed that body mass index (BMI), age and hypertension, but not AHI, showed an independent relationship with thoracic aortic diameter [47]. A somewhat different picture emerged, however, if OSA patients were subdivided into AHI groups. Compared with controls, only severe OSA patients (AHI >30 events·h−1) had a larger aortic diameter (p=0.048) [47]. One could therefore hypothesise that the adverse impact of OSA on the aorta only deploys above a certain AHI threshold, which is possibly higher than the common diagnostic threshold of AHI ≥5 events·h−1.

Another study retrospectively assessed computed tomography-derived abdominal aortic diameters at three anatomic locations in 427 subjects. After adjusting for major AAA risk factors, OSA (defined as AHI ≥10 events·h−1) was an independent risk factor for distal abdominal aortic dilation in men [53].

Prevalence of OSA among aortic disease patients

In 2003, Sampol et al. [54] reported a higher AHI in 19 patients with AD compared with 19 controls matched for age, sex and BMI (p=0.032). Although the OSA prevalence (defined by AHI >5 events·h−1) did not differ between AD patients and the matched control group (68% in each group), their findings are largely attributable to the high number (n=7) of severe OSA cases in the AD group versus one case in the control group (p=0.042). In other words, AD patients presented a higher burden of nocturnal apnoeic events and severe OSA (defined by AHI >30 events·h−1). Similar case–control studies also reported higher percentages of moderate to severe ODI in AD patients versus controls [55, 56] and two other studies concluded that AD is associated with OSA [57, 58]. These findings raise the question of whether a high AHI/severe OSA is also more prevalent in other forms of aortic disease.

An international multicentre study found that ∼40% of patients aged 18–75 years in an AAA surveillance register presented with an AHI >10 events·h−1 [59]. Cross-sectional data indicated no association of aortic diameter with AHI [59]. In order to investigate a possible association between OSA/AHI and rate of AAA expansion, Mason et al. [59] assessed patients with AAA during a median follow-up interval of 18 months. From the total cohort (n=127), patients with severe forms of OSA (ODI >30 events·h−1) had a significantly faster median yearly AAA expansion rate than patients with ODI <5 events·h−1 (p<0.05), independent of cardiovascular risk markers [59]. Other studies using indirect measures of OSA (Berlin Questionnaire) reported that about 60% of AAA patients are likely to have OSA [60]. Finally, Saruhara et al. [61] conducted a case–control study where TAA, AAA and AD patients were found to have a higher incidence of moderate to severe OSA (AHI >15 events·h−1) than controls. Table 2 summarises studies on the prevalence of OSA among aortic disease patients.

View this table:
  • View inline
  • View popup
TABLE 2

Prevalence of obstructive sleep apnoea (OSA) among aortic disease patients

Physiological studies in healthy volunteers

Three studies have investigated the pathophysiological effects of OSA using breathing manoeuvres that simulate OSA features in healthy volunteers (table 3) [62–64]. The Müller manoeuvre (simulated obstructive apnoea) has proven to be an elegant way to partially simulate acute effects of OSA without the confounding factors of profound hypoxaemia, arousals from sleep and comorbidities often present in patients with OSA [65]. In humans, the Müller manoeuvre and simulated obstructive hypopnoea (inspiration through threshold load) induced considerable changes in blood pressure and simulated obstructive hypopnoea has been shown to be associated with an increase in proximal aortic diameter and aortic area [62, 64]. The underlying forces of this increase were quantified in a second study, which concluded that simulated obstructive apnoea/hypopnoea increased aortic wall dilatory pressures [63].

View this table:
  • View inline
  • View popup
TABLE 3

Experimental studies on the association between obstructive sleep apnoea (OSA) and aortic disease in healthy volunteers

Current limitations of published studies

The aforementioned observational studies demonstrate a great deal of heterogeneity in study design approaches and in the populations studied. These variations include, for example, the facts that the treatment status of OSA was not taken into account [46], common diagnostic criteria have not been consistently applied [45, 47, 51] and some studies lacked a control group [46, 58, 60]. In studies assessing the thoracic aorta there is also a high between-study variation in methodological aspects, as studies do not use consistent anatomic landmarks [41, 44–47, 49–51]. When considering conflicting results among thoracic and abdominal diameters measured at different anatomic landmarks and the fact that, even in a single study, aortic diameters at different landmarks were distinctly affected by OSA, one may hypothesise that the aetiological significance of OSA may vary along the aorta [53]. Furthermore, specific OSA severity groups are often not reported and are most likely underpowered [41, 44–46, 50, 51, 61]. The latter represents a limitation, as the results of several studies suggest that the more severe end of the OSA spectrum (AHI ≥30 events·h−1) accounts for the impact of OSA on aortic disease [47, 49, 54, 55, 59, 61].

A significant proportion of studies in this review were submitted in the form of short notes [51, 58] or correspondence letters [45, 50], or their main outcome was something other than aortic diameter [44]. Therefore, they were originally designed with an objective other than investigating the association between OSA and aortic dilation. The possibility exists that the initial finding of a statistically significant association between OSA and aortic diameter evoked authors to selectively report their (mostly positive [45, 50, 51, 58]) data, thus creating a publication bias. Finally, studies on the prevalence of aortic disease in OSA patients are lacking. This makes it difficult to assess the actual overall impact of OSA on aortic disease.

Besides Marfan's syndrome, there are other heritable connective tissue disorders (e.g. Ehlers–Danlos syndrome and Loeys–Dietz syndrome) that are associated with aortic complications [66–69]. However, studies on the prevalence of OSA and the impact of OSA on aortic disease in these conditions are lacking. Nevertheless, it is important to keep in mind that patients with connective tissue disorders are prone to developing OSA, in general due to alterations affecting the pharyngeal soft tissue. However, because of the different pathophysiology these patients may not be representative for the usual OSA patient group.

Potential mechanisms for the association between OSA and aortic disease

The underlying mechanism(s) through which OSA may promote aortic disease and thus be a risk factor for aneurysm development are not fully understood. Studies investigating the impact of OSA on aortic disease have discussed several pathomechanisms (for thoracic aorta, see figure 2), including intrathoracic pressure changes leading to shear stress on artery walls [41, 43, 49, 51, 54, 55, 62, 63], intermittent hypoxia leading to oxidative stress and sympathetic stimulation [49, 50, 55], and arousal-induced sympathetic activation with subsequent repetitive blood pressure surges [45, 47, 50, 54, 55, 59, 61]. These mechanisms are discussed in the following section.

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Proposed mechanisms underpinning the association between obstructive sleep apnoea and thoracic aortic disease.

Intrathoracic pressure changes

Repetitive apnoeic episodes in OSA result in inspiratory effort against the occluded airway, producing negative intrathoracic pressure swings. These forces support (already elevated) blood pressure to stretch the aortic walls where blood pressure surges are highest and lead to pathological shear stress. It is known that systolic blood pressure hastens the fragmentation of fibrin and collagen deposition with secondary stiffening of the aortic wall [47]. Additional physical dilation or shear stress itself might be another important factor for developing atherosclerosis [70].

In animals, increased aortic diameters during obstructive apnoeas have been observed [71, 72]. In humans, the negative end-apnoeic pressures were quantified in one in vivo study (n=74), with a mean±sd of −53.6±2.9 cmH2O and peak pressure of −147.4 cmH2O [73]. Compared with physiological inspiration pressure of around −5 to −8 cmH2O in healthy subjects [74] or nocturnal systolic blood pressure of around 160 cmH2O (equal to 120 mmHg, which is considered the upper limit for normal nocturnal blood pressure [75]), apnoeic episodes in OSA can involve a substantial amount of energy. One study found that the extent of extra aortic dilatory force originating from simulated obstructive apnoea was 16.3 mmHg (interquartile range 12.8–19.4 mmHg; p=0.02) [63]. Therefore, a significant proportion of negative pressure is forwarded to the walls of the aorta and OSA may mechanically promote dilation. Negative intrathoracic pressure changes are also thought to contribute to aortic dilation in patients with Marfan's syndrome [41, 43]. Due to the fact that OSA subgroups are evenly distributed among AD, TAA and AAA patients, mechanisms other than solely thoracic ones must play a role in the pathogenesis of aortic disease in general [61].

Arousal-induced sympathetic activation

In OSA, cessation of the airway flow can last up to 1 min. As a consequence, blood oxygen levels decrease and carbon dioxide levels rise. Each apnoeic event is accompanied by an arousal, which leads to large transient increases in blood pressure (∼80 mmHg) despite a fall in cardiac output [76]. In OSA these events are caused by sympathetic vasoconstriction [77] and their consequences include catecholamine release [77], endothelial dysfunction [78] and probably aortic disease itself [43, 46, 47, 49, 51]. Although these pathophysiological haemodynamic and neurohumoral changes occur during sleep, their consequences persist for 24 h [79]. Hypertension is present in 72% of AD [26], 60% of TAA [23] and ∼75% of AAA [59] patients and there is consensus that the main identified risk factor for aortic dilation is systemic hypertension. Previous studies have shown that increased sympathetic drive in OSA can accelerate atherosclerosis and lead to impairment of the aortic elasticity property in the setting of hypertension [80, 81]. It has also been proposed that increased afterload from OSA-driven systemic hypertension determines aortic diameter [47]. Therefore, acute as well as chronic hypertension represents a crucial and clinically important pathway in the consequences of OSA and pathogenesis of aortic disease.

Intermittent hypoxia

The previously described short-term increases in arterial blood pressure at the end of an obstructive apnoea episode are mediated by sympathetic activity [82]. These blood pressure surges seem to be blunted during oxygen administration in OSA patients, suggesting that arterial hypoxaemia influences the autonomous nervous system in OSA patients via chemoreceptors [82]. Hypoxia is associated with the production of reactive oxygen species, which augment pro-inflammatory cytokines and enhance the production of adhesion molecules in endothelial cells/leukocytes, and promote atherosclerosis [83]. In a rodent model, intermittent hypoxia increased chemoreflex and depressed baroreflex, resulting in sympathoadrenal hyperactivity [84]. In humans, intermittent hypoxia due to OSA has been proposed to induce hypertension via increased release of vasoactive substances [85] and peripheral chemoreceptors [86]. In OSA patients, the severity of OSA is independently associated with oxidative stress caused by apnoeic events [87]. In several studies, the decrease of arterial oxygen saturation measured by pulse oximetry was correlated with the degree of aortic stiffness, a well-established disease parameter [44, 49]. Hypoxia has also been associated with increased carotid [88] and aortic root diameters [51]. Hence, hypoxia represents a potential contributor to systemic hypertension and atherosclerosis, both of which are mechanisms involved in the development of aortic disease.

Inflammatory process

In contrast to the aforementioned mechanisms, the inflammation mechanism is largely theoretical. Although some studies included in this review have considered inflammation as a potential mechanism, none specifically investigated its impact [44, 53, 55, 56, 59, 61].

It has been shown that the formation of some aortic aneurysms is a progressive inflammatory process [24, 89]. Inflammation is thought to orchestrate the various pathophysiological processes that lead to aortic aneurysms in the first place [90]. About 5% of TAA [89] and AAA [24] are inflammatory aneurysms (not to be confused with infected aortic aneurysms), which are characterised by marked aortic wall thickening with increased vascularity. They are considered an extreme form of aneurysm, where inflammation itself represents the dominant factor [24]. Anti-inflammatory drugs such as aspirin have shown promising effects in reducing aortic wall inflammation and growth rate in patients with AAA [91]. Because OSA has been suggested to have a systemic pro-inflammatory effect [92] and directly affects the vascular endothelium by promoting local inflammation [93], it is possible that OSA potentiates aortic dilation via this mechanism.

Interactions between mechanisms

The mechanisms described often act via the sympathetic nervous system and acute or chronic elevated blood pressure represents one common pathway. Blood pressure constantly oscillates (systole, diastole) as part of normal heart physiology but additional rises with OSA can cause chronic damage. It is entirely possible for mechanisms to be coupled and act in parallel. For example, negative intrathoracic pressure swings and transient blood pressure surges might synergistically encourage dilation of the aorta (already weakened by factors such as atherosclerosis) several hundred times at night. However, it is important to keep in mind that there are very few observations and high inter-individual variability of both parameters; hence, only a limited group of OSA patients might actually be affected via these mechanisms. Although some clinical studies suggest a common adverse effect of OSA on TAA, AAA and AD [61], one must consider the possibility that the pathophysiology of each disease may differ. This view is encouraged by the fact that TAA, AAA and AD do not share the same risk factors [94]. For example, atherosclerosis is positively associated with AAA [95] while evidence suggests it is negatively associated with TAA [96]. It is crucial to have a detailed knowledge of the underlying pathophysiology so that future treatments will target the right mechanism(s).

Implications for further research

Role of treatment

The present standard treatment for OSA is CPAP. It has been demonstrated that sustained and effective nocturnal CPAP treatment can lower ambulatory blood pressure, eliminate the ensuing acute haemodynamic changes during sleep and improve early signs of atherosclerosis [15, 81, 97, 98]. Determining whether aortic disease is caused by the acute effects of apnoeic episodes or the chronic structural and autonomic changes resulting from untreated OSA is likely to result in important implications for therapy [99]. In the case of acute events, CPAP treatment of OSA can abolish the acute blood pressure surges and/or intrathoracic pressure swings and lower diurnal blood pressure. However, effective CPAP treatment presents a considerable clinical challenge, as only about 30–60% of patients are adherent to CPAP [100]. Conversely, if long-term autonomic effects of OSA cause major aortic damage, there may be effective alternative therapy approaches to avoid these pathomechanisms, including (in theory) pharmacological modalities and renal sympathetic denervation [99].

In light of the proposed association between OSA and aortic disease, it is reasonable to hypothesise that CPAP might also attenuate (but not reverse) aortic root dilation in Marfan's syndrome [101, 102] and aortic aneurysm expansion rate [59]. Further steps include determining the value of CPAP treatment in the primary and secondary prevention of aortic disease in OSA patients and assessing the benefits of OSA screening in patients with aortic disease.

Threshold effect

The current literature suggests that the adverse impact of OSA on aortic dilation [49], TAA [61], AAA [53, 59, 61] and AD [54, 55, 61] only occurs above a certain severity level between moderate and severe OSA. It appears likely that there is not a straightforward linear dose–response relationship between OSA severity and aortic disease but perhaps a threshold effect [47, 54, 59]. Depending on the proposed underlying mechanisms, other measures of disease severity, such as number of apnoeas per hour, pulse transit time [103] or arousal index, may be alternative or more accurate approaches for identifying patients at risk for aortic dilation. This needs to be further investigated.

Future research

Future studies need to control for additional risk factors (primarily for hypertension) and effect modifiers. Although observational studies have, at least in part, reported an association between OSA and aortic disease, it is too early to presume a causal relationship due to the lack of randomised controlled trials. However, identifying a causal role of OSA on aortic disease is very difficult to establish, since aortic disease is a chronic condition and usually has a very long latent period before the first (and potentially fatal) symptoms emerge. This is aggravated by the fact that the genesis of aortic aneurysms and AD are believed to have multifactorial overlapping risk factors and many of them are overlapping with those of OSA. Finally, a randomised controlled trial faces the ethical issue of treating a high number of OSA patients with sham CPAP for several years.

Based on the current literature, the main points for future research are as follows. 1) The sample size of studies in this field is relatively low. High quality studies with larger sample sizes, especially in the thus far underrepresented severe OSA group (AHI >30 events·h−1), are needed to study a potential minimum threshold level for increased risk of aortic disease. 2) Prevalence studies of aortic disease in OSA patients are lacking. These numbers are needed to further quantify the association between OSA and aortic disease. 3) A further investigation of primary and secondary preventative measures of aortic disease in OSA is required. Randomised controlled trials are needed to potentially assess a causal relationship. 4) Longitudinal studies of disease parameters and clinical outcomes (e.g. aortic events in OSA) are needed in order to assess the potential long-term impact of OSA on aortic disease. 5) Prevalence studies on OSA in conditions associated with aortic problems (e.g. connective tissue diseases other than Marfan's syndrome) are needed in order to determine the impact of OSA on potentially vulnerable individuals. 6) A meta-analysis of individual patient data from relevant studies is warranted to quantify the association between thoracic aortic root size and the severity of OSA more precisely. 7) A common set of definitions and diagnostic methods for OSA are highly recommended to decrease clinical heterogeneity of studies and allow for a systematic comparison.

Conclusions

Several studies have shown an association between OSA and aortic dilation. OSA has been found to be highly prevalent in patients with aortic aneurysms and severe OSA seems to be associated with more rapid progression of AAA. Possible mechanisms that might promote aortic dilation include intrathoracic pressure changes, repetitive blood pressure surges and chronic hypertension, as well as atherosclerosis induced by intermittent hypoxia. However, there is a need for well-controlled prospective studies in order to establish a causal relationship between OSA and aortic dilation.

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Support statement: This review was funded by the Clinical Research Priority Program (CRPP) Sleep and Health from the University of Zurich. Funding information for this article has been deposited with FundRef.

  • Conflict of interest: None declared.

  • Received February 20, 2015.
  • Accepted April 29, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Young T,
    2. Palta M,
    3. Dempsey J, et al.
    The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230–1235.
    OpenUrlCrossRefPubMedWeb of Science
    1. Young T,
    2. Hutton R,
    3. Finn L, et al.
    The gender bias in sleep apnea diagnosis. Are women missed because they have different symptoms? Arch Intern Med 1996; 156: 2445–2451.
    OpenUrlCrossRefPubMedWeb of Science
    1. Peppard PE,
    2. Young T,
    3. Barnet JH, et al.
    Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177: 1006–1014.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Heinzer R,
    2. Vat S,
    3. Marques-Vidal P, et al.
    Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 2015; 3: 310–318.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Gottlieb DJ,
    2. Yenokyan G,
    3. Newman AB, et al.
    Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122: 352–360.
    OpenUrlAbstract/FREE Full Text
    1. Marin JM,
    2. Carrizo SJ,
    3. Vicente E, et al.
    Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046–1053.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Redline S,
    2. Yenokyan G,
    3. Gottlieb DJ, et al.
    Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010; 182: 269–277.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Punjabi NM,
    2. Caffo BS,
    3. Goodwin JL, et al.
    Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6: e1000132.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Haentjens P,
    2. Van Meerhaeghe A,
    3. Moscariello A, et al.
    The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007; 167: 757–764.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Kohler M,
    2. Stradling JR
    . Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010; 7: 677–685.
    OpenUrlPubMed
  8. ↵
    1. Peppard PE,
    2. Young T,
    3. Palta M, et al.
    Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–1384.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Nieto FJ,
    2. Young TB,
    3. Lind BK, et al.
    Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283: 1829–1836.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Jenkinson C,
    2. Davies RJ,
    3. Mullins R, et al.
    Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 2100–2105.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Avlonitou E,
    2. Kapsimalis F,
    3. Varouchakis G, et al.
    Adherence to CPAP therapy improves quality of life and reduces symptoms among obstructive sleep apnea syndrome patients. Sleep Breath 2012; 16: 563–569.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Pepperell JC,
    2. Ramdassingh-Dow S,
    3. Crosthwaite N, et al.
    Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204–210.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Pedrosa RP,
    2. Drager LF,
    3. de Paula LK, et al.
    Effects of OSA treatment on BP in patients with resistant hypertension: a randomized trial. Chest 2013; 144: 1487–1494.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Johnston KW,
    2. Rutherford RB,
    3. Tilson MD, et al.
    Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13: 452–458.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Kälsch H,
    2. Lehmann N,
    3. Möhlenkamp S, et al.
    Body-surface adjusted aortic reference diameters for improved identification of patients with thoracic aortic aneurysms: results from the population-based Heinz Nixdorf Recall study. Int J Cardiol 2013; 163: 72–78.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Itani Y,
    2. Watanabe S,
    3. Masuda Y, et al.
    Measurement of aortic diameters and detection of asymptomatic aortic aneurysms in a mass screening program using a mobile helical computed tomography unit. Heart Vessels 2002; 16: 42–45.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Lederle FA,
    2. Johnson GR,
    3. Wilson SE, et al.
    The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160: 1425–1430.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    National Center for Injury Prevention and Control. WISQARS Leading Causes of Death Reports, 1999–2007. http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html Date last updated: June 1, 2010. Date last accessed: April 21, 2015.
  19. ↵
    1. Isselbacher EM
    . Thoracic and abdominal aortic aneurysms. Circulation 2005; 111: 816–828.
    OpenUrlFREE Full Text
  20. ↵
    1. Bickerstaff LK,
    2. Pairolero PC,
    3. Hollier LH, et al.
    Thoracic aortic aneurysms: a population-based study. Surgery 1982; 92: 1103–1108.
    OpenUrlPubMedWeb of Science
  21. ↵
    1. Rasmussen TE,
    2. Hallett JW Jr.
    . Inflammatory aortic aneurysms. A clinical review with new perspectives in pathogenesis. Ann Surg 1997; 225: 155–164.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Reed D,
    2. Reed C,
    3. Stemmermann G, et al.
    Are aortic aneurysms caused by atherosclerosis? Circulation 1992; 85: 205–211.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Hagan PG,
    2. Nienaber CA,
    3. Isselbacher EM, et al.
    The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 2000; 283: 897–903.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Kario K
    . Obstructive sleep apnea syndrome and hypertension: ambulatory blood pressure. Hypertens Res 2009; 32: 428–432.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Young T,
    2. Palta M,
    3. Dempsey J, et al.
    Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ 2009; 108: 246–249.
    OpenUrlPubMed
  26. ↵
    1. Vasan RS,
    2. Larson MG,
    3. Levy D
    . Determinants of echocardiographic aortic root size. The Framingham Heart Study. Circulation 1995; 91: 734–740.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Lederle FA,
    2. Johnson GR,
    3. Wilson SE, et al.
    Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126: 441–449.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Stradling JR,
    2. Davies RJ
    . Sleep. 1: Obstructive sleep apnoea/hypopnoea syndrome: definitions, epidemiology, and natural history. Thorax 2004; 59: 73–78.
    OpenUrlAbstract/FREE Full Text
    1. Young T,
    2. Skatrud J,
    3. Peppard PE
    . Risk factors for obstructive sleep apnea in adults. JAMA 2004; 291: 2013–2016.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Quintana-Gallego E,
    2. Carmona-Bernal C,
    3. Capote F, et al.
    Gender differences in obstructive sleep apnea syndrome: a clinical study of 1166 patients. Respir Med 2004; 98: 984–989.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Cistulli PA,
    2. Gotsopoulos H,
    3. Sullivan CE
    . Relationship between craniofacial abnormalities and sleep-disordered breathing in Marfan's syndrome. Chest 2001; 120: 1455–1460.
    OpenUrlCrossRefPubMedWeb of Science
    1. Cistulli PA,
    2. Sullivan CE
    . Influence of maxillary morphology on nasal airway resistance in Marfan's syndrome. Acta Otolaryngol 2000; 120: 410–413.
    OpenUrlCrossRefPubMed
    1. Cistulli PA,
    2. Richards GN,
    3. Palmisano RG, et al.
    Influence of maxillary constriction on nasal resistance and sleep apnea severity in patients with Marfan's syndrome. Chest 1996; 110: 1184–1188.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Cistulli PA,
    2. Sullivan CE
    . Sleep apnea in Marfan's syndrome. Increased upper airway collapsibility during sleep. Chest 1995; 108: 631–635.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Cañadas V,
    2. Vilacosta I,
    3. Bruna I, et al.
    Marfan syndrome. Part 2: treatment and management of patients. Nat Rev Cardiol 2010; 7: 266–276.
    OpenUrlPubMed
  33. ↵
    1. Murdoch JL,
    2. Walker BA,
    3. Halpern BL, et al.
    Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 1972; 286: 804–808.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Cistulli PA,
    2. Sullivan CE
    . Sleep-disordered breathing in Marfan's syndrome. Am Rev Respir Dis 1993; 147: 645–648.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. Kohler M,
    2. Blair E,
    3. Risby P, et al.
    The prevalence of obstructive sleep apnoea and its association with aortic dilatation in Marfan's syndrome. Thorax 2009; 64: 162–166.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Rybczynski M,
    2. Koschyk D,
    3. Karmeier A, et al.
    Frequency of sleep apnea in adults with the Marfan syndrome. Am J Cardiol 2010; 105: 1836–1841.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kohler M,
    2. Pitcher A,
    3. Blair E, et al.
    The impact of obstructive sleep apnea on aortic disease in Marfan's syndrome. Respiration 2013; 86: 39–44.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Tanriverdi H,
    2. Evrengul H,
    3. Kara CO, et al.
    Aortic stiffness, flow-mediated dilatation and carotid intima-media thickness in obstructive sleep apnea: non-invasive indicators of atherosclerosis. Respiration 2006; 73: 741–750.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Serizawa N,
    2. Yumino D,
    3. Takagi A, et al.
    Obstructive sleep apnea is associated with greater thoracic aortic size. J Am Coll Cardiol 2008; 52: 885–886.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Meuleman C,
    2. Boccara F,
    3. Nguyen XL, et al.
    Is the aortic root dilated in obstructive sleep apnoea syndrome? Arch Cardiovasc Dis 2008; 101: 391–397.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Lee LC,
    2. Torres MC,
    3. Khoo SM, et al.
    The relative impact of obstructive sleep apnea and hypertension on the structural and functional changes of the thoracic aorta. Sleep 2010; 33: 1173–1176.
    OpenUrlPubMedWeb of Science
  42. ↵
    1. Pedrosa RP,
    2. Drager LF,
    3. Genta PR, et al.
    Obstructive sleep apnea is common and independently associated with atrial fibrillation in patients with hypertrophic cardiomyopathy. Chest 2010; 137: 1078–1084.
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Cicek D,
    2. Lakadamyali H,
    3. Yagbasan BD, et al.
    Obstructive sleep apnoea and its association with left ventricular function and aortic root parameters in newly diagnosed, untreated patients: a prospective study. J Int Med Res 2011; 39: 2228–2238.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Achour EC,
    2. Roche F,
    3. Romeyer-Bouchard C, et al.
    Aortic root size and sleep apnea in elderly: a cohort study. Int J Cardiol 2011; 151: 101–102.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Baguet JP,
    2. Minville C,
    3. Tamisier R, et al.
    Increased aortic root size is associated with nocturnal hypoxia and diastolic blood pressure in obstructive sleep apnea. Sleep 2011; 34: 1605–1607.
    OpenUrlPubMedWeb of Science
  46. ↵
    1. Chen YL,
    2. Su MC,
    3. Liu WH, et al.
    Influence and predicting variables of obstructive sleep apnea on cardiac function and remodeling in patients without congestive heart failure. J Clin Sleep Med 2014; 10: 57–64.
    OpenUrlPubMed
  47. ↵
    1. Tachikawa R,
    2. Hamada S,
    3. Azuma M, et al.
    Impact of obstructive sleep apnea on abdominal aortic diameters. Am J Cardiol 2014; 114: 618–623.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Sampol G,
    2. Romero O,
    3. Salas A, et al.
    Obstructive sleep apnea and thoracic aorta dissection. Am J Respir Crit Care Med 2003; 168: 1528–1531.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Naito R,
    2. Sakakura K,
    3. Kasai T, et al.
    Aortic dissection is associated with intermittent hypoxia and re-oxygenation. Heart Vessels 2012; 27: 265–270.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Zhang X,
    2. Zhang T,
    3. Zhang X, et al.
    Obstructive sleep apnea syndrome: a risk factor for Stanford's type B aortic dissection. Ann Vasc Surg 2014; 28: 1901–1908.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Yanagi H,
    2. Imoto K,
    3. Suzuki S, et al.
    Acute aortic dissection associated with sleep apnea syndrome. Ann Thorac Cardiovasc Surg 2013; 19: 456–460.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Hata M,
    2. Yoshitake I,
    3. Wakui S, et al.
    Sleep disorders and aortic dissection in a working population. Surg Today 2012; 42: 403–405.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Mason RH,
    2. Ruegg G,
    3. Perkins J, et al.
    Obstructive sleep apnea in patients with abdominal aortic aneurysms: highly prevalent and associated with aneurysm expansion. Am J Respir Crit Care Med 2011; 183: 668–674.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Bianchi VE,
    2. Herbert WG,
    3. Myers J, et al.
    Relationship of obstructive sleep apnea and cardiometabolic risk factors in elderly patients with abdominal aortic aneurysm. Sleep Breath 2015; 19: 593–598.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Saruhara H,
    2. Takata Y,
    3. Usui Y, et al.
    Obstructive sleep apnea as a potential risk factor for aortic disease. Heart Vessels 2012; 27: 166–173.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Stöwhas AC,
    2. Namdar M,
    3. Biaggi P, et al.
    The effect of simulated obstructive apnea and hypopnea on aortic diameter and BP. Chest 2011; 140: 675–680.
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    1. Clarenbach CF,
    2. Camen G,
    3. Sievi NA, et al.
    Effect of simulated obstructive hypopnea and apnea on thoracic aortic wall transmural pressures. J Appl Physiol 2013; 115: 613–617.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Rammohan HR,
    2. Murthy K,
    3. Pressman GS
    . Effects of the Mueller Maneuver on aortic area. Int J Cardiol 2014; 173: 128–129.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Hanly PJ,
    2. George CF,
    3. Millar TW, et al.
    Heart rate response to breath-hold, valsalva and Mueller maneuvers in obstructive sleep apnea. Chest 1989; 95: 735–739.
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. Pepin M,
    2. Schwarze U,
    3. Superti-Furga A, et al.
    Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000; 342: 673–680.
    OpenUrlCrossRefPubMedWeb of Science
    1. Wenstrup RJ,
    2. Meyer RA,
    3. Lyle JS, et al.
    Prevalence of aortic root dilation in the Ehlers-Danlos syndrome. Genet Med 2002; 4: 112–117.
    OpenUrlCrossRefPubMedWeb of Science
    1. Loeys BL,
    2. Chen J,
    3. Neptune ER, et al.
    A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 2005; 37: 275–281.
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Loeys BL,
    2. Schwarze U,
    3. Holm T, et al.
    Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med 2006; 355: 788–798.
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    1. Lovett JK,
    2. Rothwell PM
    . Site of carotid plaque ulceration in relation to direction of blood flow: an angiographic and pathological study. Cerebrovasc Dis 2003; 16: 369–375.
    OpenUrlCrossRefPubMedWeb of Science
  63. ↵
    1. Peters J,
    2. Kindred MK,
    3. Robotham JL
    . Transient analysis of cardiopulmonary interactions. I. Diastolic events. J Appl Physiol 1988; 64: 1506–1517.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Peters J,
    2. Kindred MK,
    3. Robotham JL
    . Transient analysis of cardiopulmonary interactions. II. Systolic events. J Appl Physiol 1988; 64: 1518–1526.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Suzuki M,
    2. Ogawa H,
    3. Okabe S, et al.
    Digital recording and analysis of esophageal pressure for patients with obstructive sleep apnea-hypopnea syndrome. Sleep Breath 2005; 9: 64–72.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Rhoades RA,
    2. Bell DR, eds
    . Medical Physiology: Principles for Clinical Medicine. 4th Edn. Philadelphia, Lippincott Williams and Wilkins, 2013.
  67. ↵
    1. Pickering TG,
    2. Hall JE,
    3. Appel LJ, et al.
    Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005; 45: 142–161.
    OpenUrlCrossRef
  68. ↵
    1. Garpestad E,
    2. Parker JA,
    3. Katayama H, et al.
    Decrease in ventricular stroke volume at apnea termination is independent of oxygen desaturation. J Appl Physiol 1994; 77: 1602–1608.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Somers VK,
    2. Dyken ME,
    3. Clary MP, et al.
    Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897–1904.
    OpenUrlCrossRefPubMedWeb of Science
  70. ↵
    1. Kato M,
    2. Roberts-Thomson P,
    3. Phillips BG, et al.
    Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102: 2607–2610.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Carlson JT,
    2. Hedner J,
    3. Elam M, et al.
    Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103: 1763–1768.
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    1. Tsioufis C,
    2. Thomopoulos K,
    3. Dimitriadis K, et al.
    The incremental effect of obstructive sleep apnoea syndrome on arterial stiffness in newly diagnosed essential hypertensive subjects. J Hypertens 2007; 25: 141–146.
    OpenUrlCrossRefPubMedWeb of Science
  73. ↵
    1. Drager LF,
    2. Bortolotto LA,
    3. Figueiredo AC, et al.
    Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176: 706–712.
    OpenUrlCrossRefPubMedWeb of Science
  74. ↵
    1. Leuenberger U,
    2. Jacob E,
    3. Sweer L, et al.
    Surges of muscle sympathetic nerve activity during obstructive apnea are linked to hypoxemia. J Appl Physiol 1995; 79: 581–588.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Savransky V,
    2. Nanayakkara A,
    3. Li J, et al.
    Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007; 175: 1290–1297.
    OpenUrlCrossRefPubMedWeb of Science
  76. ↵
    1. Dematteis M,
    2. Julien C,
    3. Guillermet C, et al.
    Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008; 177: 227–235.
    OpenUrlCrossRefPubMedWeb of Science
  77. ↵
    1. Kanagy NL,
    2. Walker BR,
    3. Nelin LD
    . Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 2001; 37: 511–515.
    OpenUrlCrossRef
  78. ↵
    1. Lesske J,
    2. Fletcher EC,
    3. Bao G, et al.
    Hypertension caused by chronic intermittent hypoxia – influence of chemoreceptors and sympathetic nervous system. J Hypertens 1997; 15: 1593–1603.
    OpenUrlCrossRefPubMedWeb of Science
  79. ↵
    1. Yamauchi M,
    2. Nakano H,
    3. Maekawa J, et al.
    Oxidative stress in obstructive sleep apnea. Chest 2005; 127: 1674–1679.
    OpenUrlCrossRefPubMedWeb of Science
  80. ↵
    1. Lefebvre B,
    2. Pépin JL,
    3. Baguet JP, et al.
    Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008; 32: 113–120.
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Pacini D,
    2. Leone O,
    3. Turci S, et al.
    Incidence, etiology, histologic findings, and course of thoracic inflammatory aortopathies. Ann Thorac Surg 2008; 86: 1518–1523.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Eagleton MJ
    . Inflammation in abdominal aortic aneurysms: cellular infiltrate and cytokine profiles. Vascular 2012; 20: 278–283.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Lindholt JS,
    2. Sorensen HT,
    3. Michel JB, et al.
    Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovascular Surg 2008; 42: 329–334.
    OpenUrlAbstract/FREE Full Text
  84. ↵
    1. Nadeem R,
    2. Molnar J,
    3. Madbouly EM, et al.
    Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. J Clin Sleep Med 2013; 9: 1003–1012.
    OpenUrlPubMed
  85. ↵
    1. Jelic S,
    2. Padeletti M,
    3. Kawut SM, et al.
    Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117: 2270–2278.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Elefteriades JA,
    2. Farkas EA
    . Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010; 55: 841–857.
    OpenUrlCrossRefPubMedWeb of Science
  87. ↵
    1. Golledge J,
    2. Muller J,
    3. Daugherty A, et al.
    Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006; 26: 2605–2613.
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Achneck H,
    2. Modi B,
    3. Shaw C, et al.
    Ascending thoracic aneurysms are associated with decreased systemic atherosclerosis. Chest 2005; 128: 1580–1586.
    OpenUrlCrossRefPubMedWeb of Science
  89. ↵
    1. Lattimore JD,
    2. Celermajer DS,
    3. Wilcox I
    . Obstructive sleep apnea and cardiovascular disease. J Am Coll Cardiol 2003; 41: 1429–1437.
    OpenUrlCrossRefPubMedWeb of Science
  90. ↵
    1. Ali NJ,
    2. Davies RJ,
    3. Fleetham JA, et al.
    The acute effects of continuous positive airway pressure and oxygen administration on blood pressure during obstructive sleep apnea. Chest 1992; 101: 1526–1532.
    OpenUrlCrossRefPubMedWeb of Science
  91. ↵
    1. Gottlieb DJ
    . Sleep apnea and the risk of atrial fibrillation recurrence: structural or functional effects? J Am Heart Assoc 2014; 3: e000654.
    OpenUrlFREE Full Text
  92. ↵
    1. Weaver TE,
    2. Sawyer AM
    . Adherence to continuous positive airway pressure treatment for obstructive sleep apnoea: implications for future interventions. Indian J Med Res 2010; 131: 245–258.
    OpenUrlPubMedWeb of Science
  93. ↵
    1. Cistulli PA,
    2. Wilcox I,
    3. Jeremy R, et al.
    Aortic root dilatation in Marfan's syndrome: a contribution from obstructive sleep apnea? Chest 1997; 111: 1763–1766.
    OpenUrlCrossRefPubMed
  94. ↵
    1. Verbraecken J,
    2. Paelinck BP,
    3. Willemen M, et al.
    Aortic root diameter and nasal intermittent positive airway pressure treatment in Marfan's syndrome. Clin Genet 2003; 63: 131–134.
    OpenUrlCrossRefPubMed
  95. ↵
    1. Schwartz DJ
    . The pulse transit time arousal index in obstructive sleep apnea before and after CPAP. Sleep Med 2005; 6: 199–203.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
Previous
Back to top
View this article with LENS
Vol 46 Issue 2 Table of Contents
European Respiratory Journal: 46 (2)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The impact of obstructive sleep apnoea on the aorta
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The impact of obstructive sleep apnoea on the aorta
Thomas Gaisl, Daniel J. Bratton, Malcolm Kohler
European Respiratory Journal Aug 2015, 46 (2) 532-544; DOI: 10.1183/09031936.00029315

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The impact of obstructive sleep apnoea on the aorta
Thomas Gaisl, Daniel J. Bratton, Malcolm Kohler
European Respiratory Journal Aug 2015, 46 (2) 532-544; DOI: 10.1183/09031936.00029315
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Implications for further research
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Sleep medicine
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Corticosteroid and immunosuppressive therapies for cardiac sarcoidosis
  • Diagnostic, prognostic and differential-diagnostic relevance of pulmonary hemodynamics during exercise – a systematic review
  • Drug-induced interstitial lung disease
Show more Review

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society